Abstract
Introduction: Decreasing body temperature on first follow-up visit—relative to discharge—predicts early rehospitalization in heart failure (HF). We studied whether admission-to-discharge temperature reduction was associated with increased HF rehospitalization in the ESCAPE trial. Methods: We compared patients with or without ≥1 °C decrease in temperature from admission-to-discharge. The study endpoint was rehospitalization due to HF for up to 6 months after discharge. Results: Among 354 patients (average age 57 years, 73% men) with recorded admission and discharge temperature, 22 (6.2%) had an admission-to-discharge temperature reduction ≥1 ºC. Patients with admission-to-discharge temperature reduction ≥1 ºC had higher frequency of rehospitalization for HF (68.2% vs. 44.3%, estimated odds ratio [OR] 2.697, 95% confidence interval [CI] 1.072–6.787, P = 0.029) despite a significantly higher admission temperature. On multivariate analysis, admission-to-discharge temperature reduction ≥1 ºC predicted rehospitalization for HF (OR 2.02, 95% CI 1.028–3.966, P = 0.041) after adjustment for age, BMI, baseline Na, creatinine, ejection fraction and discharge NYHA class. A standard logistic model treating temperature change as a continuous variable, and a model using a restricted cubic spline, did not demonstrate a statistically significant relationship between temperature reduction and HF rehospitalization. Subsequently, an altered logistic model was fit expressing the log odds of HF rehospitalization as a piecewise linear function of temperature decrease; this model did demonstrate statistical significance (P = 0.013) with an estimated odds ratio of 1.140 per 0.1 ºC beyond 0.5 ºC. Conclusion: Admission-to-discharge temperature reduction ≥1 ºC is an unfavorable prognostic sign associated with future rehospitalization due to HF.
Translated title of the contribution | Admission-to-discharge temperature reduction in decompensated heart failure is associated with rehospitalization |
---|---|
Original language | English |
Pages (from-to) | 649-655 |
Number of pages | 7 |
Journal | Herz |
Volume | 43 |
Issue number | 7 |
DOIs | |
State | Published - Nov 1 2018 |
Bibliographical note
Publisher Copyright:© 2017, Springer Medizin Verlag GmbH.
Funding
The ESCAPE trial is conducted and supported by the NHLBI in collaboration with the ESCAPE Study Investigators. This article was prepared using a limited access dataset obtained from the NHLBI and does not necessarily reflect the opinions or views of the ESCAPE trial investigators or the NHLBI. H.R. Omar and M. Guglin declare that they have no competing interests. R. Charnigo has been a co-investigator on two grants from AstraZeneca and has traded IBM stock and/or stock options. This article does not contain any studies with human participants or animals performed by any of the authors.
Funders | Funder number |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) | |
AstraZeneca |
Keywords
- Heart failure
- Hypothermia
- Morbidity
- Mortality
- Rehospitalization
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine